Brainstorm Cell Therapeutics (BCLI) Upgraded to Hold at ValuEngine

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

Separately, Maxim Group set a $9.00 target price on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research note on Thursday, March 8th.

How to Become a New Pot Stock Millionaire

Brainstorm Cell Therapeutics stock traded up $0.06 during mid-day trading on Monday, hitting $3.21. 38,473 shares of the company’s stock traded hands, compared to its average volume of 59,816. The company has a market capitalization of $60.07, a P/E ratio of -12.35 and a beta of 1.86. Brainstorm Cell Therapeutics has a one year low of $2.88 and a one year high of $5.18.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.11. equities research analysts predict that Brainstorm Cell Therapeutics will post -0.66 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in the business. Clearline Capital LP bought a new stake in Brainstorm Cell Therapeutics during the 4th quarter valued at $208,000. Deutsche Bank AG raised its stake in Brainstorm Cell Therapeutics by 330.0% during the 4th quarter. Deutsche Bank AG now owns 98,590 shares of the biotechnology company’s stock valued at $386,000 after acquiring an additional 75,664 shares in the last quarter. Renaissance Technologies LLC raised its stake in Brainstorm Cell Therapeutics by 396.9% during the 4th quarter. Renaissance Technologies LLC now owns 114,550 shares of the biotechnology company’s stock valued at $449,000 after acquiring an additional 91,495 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Brainstorm Cell Therapeutics by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock valued at $2,733,000 after acquiring an additional 17,657 shares in the last quarter. 9.54% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Brainstorm Cell Therapeutics (BCLI) Upgraded to Hold at ValuEngine” was reported by WKRB News and is the property of of WKRB News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.wkrb13.com/2018/04/03/brainstorm-cell-therapeutics-bcli-upgraded-to-hold-at-valuengine.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply